Abstract
Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
CNS & Neurological Disorders - Drug Targets
Title:Conference Report
Volume: 11 Issue: 3
Author(s): Stephen D. Skaper
Affiliation:
Abstract: Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
Export Options
About this article
Cite this article as:
D. Skaper Stephen, Conference Report, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672427
DOI https://dx.doi.org/10.2174/187152712800672427 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Patents on Therapeutic Potential and Delivery of Hydroge n Sulfide
Recent Patents on Drug Delivery & Formulation A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology The Roles of Mesenchymal Stem Cells in Tissue Repair and Disease Modification
Current Stem Cell Research & Therapy Pharmacological Histone Deacetylation Distinguishes Transcriptional Regulators
Current Topics in Medicinal Chemistry Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Current Alzheimer Research Disease Outcome, Alexithymia and Depression are Differently Associated with Serum IL-18 Levels in Acute Stroke
Current Neurovascular Research Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Melatonin Alleviates Pyroptosis of Retinal Neurons Following Acute Intraocular Hypertension
CNS & Neurological Disorders - Drug Targets Variability in Response to Cardiovascular Drugs
Current Clinical Pharmacology tPA in the Central Nervous System: Relations Between tPA and Cell Surface LRPs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Angiogenesis in Glioblastoma Multiforme: Navigating the Maze
Anti-Cancer Agents in Medicinal Chemistry Commentary 2 (The Contribution of Glial Cells and Water Channel Aquaporin-4 in the Neuropathology of Cardiac Arrest is Still Ignored)
CNS & Neurological Disorders - Drug Targets REM Sleep Loss and Recovery Regulates Blood-Brain Barrier Function
Current Neurovascular Research Cerebral Ischemia and Angiogenesis
Current Neurovascular Research Tamoxifen as a Powerful Neuroprotectant in Experimental Stroke and Implications for Human Stroke Therapy
Recent Patents on CNS Drug Discovery (Discontinued) A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Tityus serrulatus Scorpion Venom and Toxins: An Overview
Protein & Peptide Letters